• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zymeworks Inc. - Common Stock (NQ:ZYME)

    17.89 -0.17 (-0.94%)
    Streaming Delayed Price Updated: 10:10 AM EDT, Oct 13, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 52,510
    Open 18.10
    Bid (Size) 17.89 (1)
    Ask (Size) 17.95 (3)
    Prev. Close 18.06
    Today's Range 17.88 - 18.49
    52wk Range 9.030 - 18.35
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit
    Zymeworks discontinues ZW171 development after Phase 1 findings, refocusing on other cancer therapies in its pipeline, including ZW191 and ZW251. 
    Via Benzinga

    Performance

    YTD
    +21.0%
    +21.0%
    1 Month
    +13.7%
    +13.7%
    3 Month
    +34.0%
    +34.0%
    6 Month
    +62.6%
    +62.6%
    1 Year
    +34.5%
    +34.5%

    More News

    Read More
    Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
    Via Stocktwits
    Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager
    From Zymeworks Inc.
    Via GlobeNewswire
    Earnings Scheduled For August 7, 2025
    Via Benzinga
    Earnings Scheduled For May 8, 2025
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Which stocks are moving after the closing bell on Friday?
    Via Chartmill
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge
    Via Stocktwits
    Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    TD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer Therapy
    Via Stocktwits
    Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks Announces Participation in Upcoming Investor Conferences
    From Zymeworks Inc.
    Via GlobeNewswire
    Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting
    From Zymeworks Inc.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Zymeworks Inc. - Common Stock publicly traded?
    Yes, Zymeworks Inc. - Common Stock is publicly traded.
    What exchange does Zymeworks Inc. - Common Stock trade on?
    Zymeworks Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Zymeworks Inc. - Common Stock?
    The ticker symbol for Zymeworks Inc. - Common Stock is ZYME on the Nasdaq Stock Market
    What is the current price of Zymeworks Inc. - Common Stock?
    The current price of Zymeworks Inc. - Common Stock is 17.89
    When was Zymeworks Inc. - Common Stock last traded?
    The last trade of Zymeworks Inc. - Common Stock was at 10/13/25 10:10 AM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.